Nitzoxanide 展示出抗乙肝病毒效力

bbbzzzxxx

以下是引用小茗在2006-11-23 15:55:25的发言：

你们看一下这些网站，把治肝药宣传的多好，我都动心了！

           www.zzcok.com

           www.gan999.com

有人用吗？给点意见

扯淡！至今已肝没有特效药，目前没有比干扰素、拉米夫定、阿地福韦脂、博路定更好的治疗效果的其它治肝药品。网上的治肝特效药不计其数，不只上述二只，若有用已肝早就能治逾。

2002落叶

2002 年末, 勒马克实验室( Romark Laborato2ries) 宣布,美国药品和食品监督管理局( FDA) 已经批准使用“Alinia (商标) (nitazoxanide) 口服混悬液”治疗隐孢子属和贾第蓝氏鞭毛虫引起的儿童腹泻。Alinia 是FDA 批准的第一个和唯一的用于治疗隐孢子虫属的药物,也是40 多年来批准用于治疗贾第虫属的第一种新药 。目前在澳大利亚、新西兰、美国、加拿大、墨西哥等国家上市,我国还没有进口,国内也无厂家生产。但NTZ 作为一种有效的、广谱的抗动物与人体寄生虫、细菌和真菌感染的药物,具有广阔的应用前景。

值得一提的是,NTZ 在治疗艾滋病人的隐孢子虫病方面也有疗效。艾滋病患者由于免疫功能缺失,隐孢子虫感染尤为严重,并将引发持续性腹泻,这成为艾滋病患者高病死率的原因之一 。Beat2 rice 等对100 名赞比亚儿童(其中50 名HIV 阳性,50 名HIV 阴性) 用NTZ 治疗隐孢子虫感染引起的腹泻。对照试验结果表明,HIV 血清阴性患儿用NTZ 治疗3 天后,粪便中卵囊排出情况比服用安慰剂的对照组有所好转,并且病死率也下降了,HIV血清阳性组患儿病情也有好转,经长期、高剂量治疗后可能会更有效。另有报道.NTZ 可治疗与艾滋
病相关、对甲硝达唑有抗药性的贾第鞭毛虫病。Alain 等也报道曾用NTZ 成功治疗艾滋病患者肠道小孢子虫( Enterocytoozoon bieneusi) 感染。

NTZ 具有良好的耐受性,服用未见严重的不良反应。在临床试验的受试者中,仅有不足1 %的人会出现轻微的、短暂的副作用,且主要与胃肠道反应有关,如恶心、厌食、胀气等。但血液学、临床化学或尿液分析均未见异常 。
综上所述,NTZ 是一种有效的抗肠道寄生虫、细菌感染的新药,具有疗效佳、市场应用广的特点,值得关注。但其确切的抗虫、杀菌机制仍需进一步探明,单一的口服剂型也有待进一步开发。

什么权威报道说此药可以抗HBV?请给个链接

cmc518518

什么时候上市啊?关注!

走遍四方

硝唑尼特,就是这个吧

coolmanht

有没人吃过呢？？？？？？？？？？？？？？？？？？？？？？？

暗夜天使

只用过甲硝唑，没用过硝唑尼特

lemonades

World J Gastroenterol. 2009 Apr 21;15(15):1805-8.

Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides.
Keeffe EB, Rossignol JF.

Romark Laboratories, LC, Sausalito, California 94965, United States. [email protected]

Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium parvum. More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis C virus was recognized in in vitro systems. These basic studies led to phase II clinical trials that demonstrated the safety and efficacy of nitazoxanide in combination with peginterferon, with or without ribavirin, in the treatment of chronic hepatitis C genotype 4. The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin. In very preliminary studies of patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led to loss of hepatitis B e antigen in the majority of patients and hepatitis B surface antigen in approximately a quarter of patients. Randomized controlled studies of naive and nonresponder patients with chronic hepatitis C genotype 1 are underway, new second generation and controlled release thiazolides are being developed, and future studies of patients with chronic hepatitis B are planned.

已经在研发第二代药物了，看上去II期临床已经证明安全了。目前主要集中在HCV，而且是联用干扰素。HBV还只是有计划

lemonades

Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.

Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC20007, USA. [email protected]

Nitazoxanide (NTZ), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C. In this report, we characterize the activities of NTZ and its active metabolite, tizoxanide (TIZ), along with other thiazolides against hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in standard antiviral assays. NTZ and TIZ exhibited potent inhibition of both HBV and HCV replication. NTZ was equally effective at inhibiting replication of lamivudine (LMV) and adefovir dipovoxil (ADV)-resistant HBV mutants and against 2'-C-methyl cytidine (2'CmeC) and telaprevir (VX-950)-resistant HCV mutants. NTZ displayed synergistic interactions with LMV or ADV against HBV, and with recombinant interferon alpha-2b (IFN) or 2'CmeC against HCV. Pre-treatment of HCV replicon-containing cells with NTZ potentiated the effect of subsequent treatment with NTZ plus IFN, but not NTZ plus 2'CmeC. NTZ induced reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but did not affect HBV RNA transcription. NTZ, TIZ, and other thiazolides are promising new antiviral agents that may enhance current or future anti-hepatitis therapies.

对拉米和阿德耐药的都有效，和拉米或阿德或干扰素有协同作用。 不影响HBV RNA的转录。

[ 本帖最后由 lemonades 于 2009-11-5 09:09 编辑 ]

走遍四方

原帖由 lemonades 于 2009-11-5 09:02 发表
Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Korba BE, Montero AB ...

produced by 2.2.15 cells  是什么意思. lemon

lemonades

2.2.15 cells是一种能产生HBsAg, HBeAg, HBcAg的肝细胞，现在普遍用作体外模型